JMP Securities analyst Roy Buchanan raised the firm’s price target on Dynavax to $25 from $22 and keeps an Outperform rating on the shares. The company’s FY22 results were in line with last month’s pre-announcement and its 2023 guidance looks to continued strong HEPLISAV-B growth, the analyst tells investors in a research note. The firm adds that it "remains enthusiastic" for the advantageous uniqueness of HEPLISAV-B in a growing market and for management’s ability to execute on additional pipeline opportunities.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on DVAX:
- Dynavax reports Q4 EPS 45c, consensus 0c
- Dynavax Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Full Year 2023 Financial Guidance
- Dynavax reports results from Phase 1 trial of shingles vaccine Z-1018
- Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial Highlights and Phase 1 Shingles Topline Results
- Dynavax reports Q4 preliminary HEPLISAV-B net product revenue $35M
